Yunnan Hongxiang Yixintang (002727) Fair Value & Analysis
Healthcare · CN · Market cap 6.4B CNY (≈ $959M) · ISIN CNE100001WJ8
What is Yunnan Hongxiang Yixintang really worth?
A solid business, but trading 19% above our fair value of ¥9.45.
Strengths
Risks
For context
Fair value as of: Aug 22, 2026
From 26 valuation models · updated 14 days ago
Share price −2.3% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder.
- The price sits in the upper half of our model range, so the margin of safety is thin.
- The data supports the verdict: every model runs on fully documented inputs.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 22, 2026.
How to read this chart
60‑month range ¥9.59 – ¥43.27 · fair‑value band ¥7.09 – ¥11.81 · the ¥11.26 price screens above the ¥9.45 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 22, 2026.
Analysis
Yunnan Hongxiang Yixintang (002727) currently trades at ¥11.26, while our model-based Fair Value estimate is ¥9.45, implying the stock looks roughly 19.1% overvalued today. The Quality Score stands at 65/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of ¥37.30 per share, and 16 of the 26 models we run sit above the ¥11.26 price. Bear case: the Earnings-Based group reads lowest at ¥6.46, and 10 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Yunnan Hongxiang Yixintang generated revenue of 17.0B CNY at a net margin of 1.6%. Revenue declined 7.0% year over year. It earns a return on equity of 3.7%. The balance sheet holds a net cash position of 1.4B CNY. Fundamentals as of Aug 22, 2026
Our scenario range runs from ¥7.09 (bear case) to ¥11.81 (bull case); at ¥11.26, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 32% below its 52-week high and 5% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −21% fair-value upside, at −16%, 002727 screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly ¥0.0544 per share, which is 0.6 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: DCF Models (¥37.30) versus Earnings-Based (¥6.46). Highest evidence: FCF DCF (77).
Notify me when 002727 reaches fair value
Put 002727 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 36
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Yixintang Pharmaceutical Group Co., Ltd., together with its subsidiary, engages in the pharmaceutical retail chain and pharmaceutical distribution business.
Full company description
Yixintang Pharmaceutical Group Co., Ltd., together with its subsidiary, engages in the pharmaceutical retail chain and pharmaceutical distribution business. The company is involved in the wholesale, retail, leasing, and operation of medical devices; sale of food, disinfectants, disinfection equipment, sanitary products and disposable medical products, household appliances, adult toys, agricultural and sideline products, cosmetics, and daily sundries and necessities; manufacturing of glasses; provision of value-added telecommunications, Internet live broadcast technology, and Internet information services for medicines, as well as clinic and foot bath services; operation of aquatic wild animals and call center; retail of publications; and decoction services for Chinese herbal medicines. It also engages in the agency sale of single-purpose commercial prepaid cards and China sports lottery; and maternal and child care activities. In addition, the company provides health care, housekeeping, amusement park, residents' daily life, and health consulting service, as well as business agency, ticket agency, personal Internet live broadcast, remote health management, corporate member points management, food delivery, and road freight transportation services. Further, it is involved in the import and export of goods and technology; wholesale of pet food and supplies; and wholesale of clothing and accessories. Additionally, the company sells products online. The company was formerly known as Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd. and changed its name to Yixintang Pharmaceutical Group Co., Ltd. in June 2019. Yixintang Pharmaceutical Group Co., Ltd. was founded in 2000 and is headquartered in Kunming, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Yunnan Hongxiang Yixintang reported revenue of 17.3B CNY in FY2025 versus 14.6B CNY in FY2021, a compound +4.4%/yr. Reported net income was 263M CNY in FY2025, compounding −26.9%/yr from FY2021.
of which total revenue +16.6 % · buybacks/dilution −2.9 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
002727 screens 19% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 57 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$38.86 | HK$33.31 | −14% |
| Alibaba Health Information Technology Limited 0241 | HK$3.26 | HK$2.04 | −37% |
| Yifeng Pharmacy Chain Co 603939 | ¥22.90 | ¥29.07 | +27% |
| DaShenLin Pharmaceutical Group 603233 | ¥18.79 | ¥23.86 | +27% |
| MedPlus Health Services Limited MEDPLUS | ₹656.80 | ₹191.97 | −71% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥13.44 | ¥10.57 | −21% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥16.31 | ¥10.05 | −38% |
| ShuYu Civilian Pharmacy Corp 301017 | ¥13.30 | ¥5.91 | −56% |
| Apotea AB APOTEA | kr 74.15 | kr 46.46 | −37% |
| Luyan Pharma Co 002788 | ¥10.96 | ¥15.91 | +45% |
Compare Yunnan Hongxiang Yixintang with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Yunnan Hongxiang Yixintang (002727) overvalued or undervalued?
What is the fair value of 002727?
What is the quality score of 002727?
What is the revenue of Yunnan Hongxiang Yixintang (002727)?
What is the net profit margin of 002727?
Does Yunnan Hongxiang Yixintang pay a dividend?
Watch Yunnan Hongxiang Yixintang in the live analysis
One click puts Yunnan Hongxiang Yixintang on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.